Incorporating target heterogeneity in drug design

Journal of Cellular Biochemistry

Volumn 84, Issue SUPPL. 37, 2001, Pages 82-88

  Velazquez Campoy, Adrian ^a   Freire, Ernesto ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

AIDS; Drug design; Drug resistance; Genomic diversity; HIV

Indexed keywords

AG 1776; INDINAVIR; KNI 577; KNI 764; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG; PROTEINASE;

BINDING AFFINITY; BINDING SITE; CONFERENCE PAPER; DRUG CONFORMATION; DRUG DESIGN; DRUG STRUCTURE; GENETIC VARIABILITY; GEOMETRY; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEINASE INHIBITION; THERMODYNAMICS; DRUG EFFECT; DRUG RESISTANCE; FORECASTING; GENETICS; HUMAN; METABOLISM; MUTATION; PHYSIOLOGY; REVIEW;

HUMAN IMMUNODEFICIENCY VIRUS 1;

BINDING SITES; DRUG DESIGN; DRUG RESISTANCE; FORECASTING; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; MUTATION; THERMODYNAMICS; VARIATION (GENETICS);

EID: 0036166136     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10068     Document Type: Conference Paper

References (19)

1. Molecular basis of HIV-1 protease drug resistance: Structural analysis of mutant proteases complexed with cyclic urea inhibitors
2. Counteracting HIV-1 protease drug resistance: Structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities
3. Structural basis of drug resistance for the V82A mutant of HIV-1 protease: Backbone flexibility and substrate repacking
4. GenBank
5. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
6. Binding of small molecules to macromolecular targets: Evaluation of conformational entropy changes
7. Structure based calculation of the equilibrium folding pathway of proteins. Correlation with hydrogen exchange protection factors
8. Characterization of human immunodeficiency virus type 1 variants with increased resistant to a C2-symmetric protease inhibitor
9. Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases
10. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease
11. The Key-Lock theory and the induced fit theory
12. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: Relationship to drug resistance
13. The structural stability of binding sites. Consequences for binding affinity and cooperativity
14. The structural stability of the HIV-1 protease
15. The thermodynamic basis of resistance to HIV-1 protease inhibition. Calorimetric analysis of the V82F/I84V active site resistant mutant
16. The binding energetics of first and second generation HIV-1 protease inhibitors: Implications for drug design
17. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes
18. Dissection of binding energy with native and ligand-bound protein stabilities: Determining the affinity of ultratight-binding inhibitors of HIV-1 protease and its drug resistance mutants
19. JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1